AAV - Bioprocess Development Forum

Articles Downstream Downstream Events

November 1, 2024

CytivaThe biotherapeutics pipeline is evolving and so are the tools to purify and manufacture therapeutic…

Jeanne Linke

Articles Downstream

December 15, 2023

As demand for AAV vectors grows, so does the need for scalable and cost-efficient purification...

admin-element

Articles BioPharma

August 25, 2023

Knowledge of adeno-associated variant's infection pathway is based on only a few serotypes.

admin-element

Articles Upstream

May 19, 2023

Adeno-associated virus (AAV) is the most common vector for gene therapy, yet there’s much room…

admin-element

Articles

March 10, 2023

Therapeutic biologics are thriving, according to Zhou Jiang, director Cell Culture Services at Cytiva.

admin-element

Articles Upstream

January 12, 2023

Improving the performance of a scalable AAV process in Xcellerex™ XDR-10 and XDR-200 bioreactor...

admin-element